MetaCap

Rezolute (RZLT) vs Shattuck Labs (STTK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Shattuck Labs (STTK) has outperformed Rezolute (RZLT) over the past year, gaining 119.7% versus a loss of 60.1%. Over five years, RZLT leads with a -26.9% price change compared with -52.0% for STTK. Rezolute is the larger company by market cap ($465.6 million vs $454.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RZLT-60.12%STTK+119.70%
+316%+106%-105%
Nov 21, 20251 yearNov 20, 2026
RZLT-32.41%STTK-52.55%
+94%-3%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RZLT versus STTK key metrics
MetricRZLTSTTK
Share price$3.92$4.46
Market cap$465.58M$454.22M
1-day change-6.67%-1.98%
YTD return+66.10%+22.19%
1-year return-60.12%+119.70%
5-year return-26.87%-51.99%
EPS (TTM)$-0.76$-0.47
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.00M
Revenue growth (YoY)—-82.52%
Net income (latest FY)$-77.60M$-48.81M
Operating margin—-5150.80%
Net margin—-4880.90%
52-week high$11.17$8.33
52-week low$1.07$1.93
Distance from 52-week high-64.89%-46.46%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+175.51%+245.29%
Average volume1.66M1.20M
Shares outstanding118.77M101.84M
Employees6340
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • STTK has outperformed RZLT by 179.8 percentage points over the past year.

About Rezolute

RZLT stock →

Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.

Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees

About Shattuck Labs

STTK stock →

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.

Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees

RZLT vs STTK FAQ

Which is bigger, Rezolute or Shattuck Labs?

Rezolute (RZLT) is larger, with a market capitalization of $465.58M compared with $454.22M for Shattuck Labs (STTK).

Which stock has performed better over the past year, RZLT or STTK?

STTK returned +119.70% over the past 12 months, compared with -60.12% for RZLT (price return, excluding dividends). Past performance does not predict future results.

Are Rezolute and Shattuck Labs in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons